NAS:BRKR (USA) Also trade in: Germany

Bruker Corp

$ 45.55 -0.22 (-0.48%)
Volume: 744,508 Avg Vol (1m): 819,409
Market Cap $: 7.14 Bil Enterprise Value $: 7.19 Bil
P/E (TTM): 38.62 P/B: 7.92
Earnings Power Value 13.26
Net Current Asset Value 0.09
Tangible Book 2.28
Projected FCF 14.06
Median P/S Value 23.61
Graham Number 7.77
Peter Lynch Value 19.42
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 7/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.89
Cash-To-Debt ranked lower than
65.90% of 261 companies
in the Diagnostics & Research industry.
Industry Max: 32990, Med: 3.52, Min: 0.01
BRKR: 0.89
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.13, Med: 1.28, Max: 9.3
Current: 0.89
0.13
9.3
Equity-to-Asset 0.41
Equity-to-Asset ranked lower than
80.33% of 239 companies
in the Diagnostics & Research industry.
Industry Max: 0.97, Med: 0.61, Min: -2.81
BRKR: 0.41
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.14, Med: 0.42, Max: 0.69
Current: 0.41
0.14
0.69
Debt-to-Equity 0.37
Debt-to-Equity ranked lower than
65.85% of 164 companies
in the Diagnostics & Research industry.
Industry Max: 22.86, Med: 0.36, Min: 0.01
BRKR: 0.37
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0.07, Med: 0.37, Max: 1.72
Current: 0.37
0.07
1.72
Debt-to-EBITDA 1.02
Debt-to-EBITDA ranked higher than
52.59% of 116 companies
in the Diagnostics & Research industry.
Industry Max: 77.72, Med: 1.77, Min: 0.03
BRKR: 1.02
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: 0.83, Med: 1.53, Max: 2.04
Current: 1.02
0.83
2.04
Interest Coverage 22.20
Interest Coverage ranked lower than
63.19% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 15605.52, Med: 76.01, Min: 0.54
BRKR: 22.2
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 9.84, Med: 14.93, Max: 28.84
Current: 22.2
9.84
28.84
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.60
DISTRESS
GREY
SAFE
Beneish M-Score -2.16
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 24.51%
WACC 11.96%

Profitability & Growth : 7/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 14.18
Operating Margin ranked higher than
73.14% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 53.36, Med: -0.59, Min: -70300
BRKR: 14.18
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 7.24, Med: 11.13, Max: 14.18
Current: 14.18
7.24
14.18
Net Margin % 9.53
Net Margin ranked higher than
65.98% of 241 companies
in the Diagnostics & Research industry.
Industry Max: 41.13, Med: -2.48, Min: -119600
BRKR: 9.53
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: 3.13, Med: 5.93, Max: 9.53
Current: 9.53
3.13
9.53
ROE % 21.92
ROE ranked higher than
73.97% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 61.7, Med: -6.75, Min: -12038.19
BRKR: 21.92
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: 7.03, Med: 14.87, Max: 22.27
Current: 21.92
7.03
22.27
ROA % 9.27
ROA ranked higher than
67.18% of 262 companies
in the Diagnostics & Research industry.
Industry Max: 1174.65, Med: -4.54, Min: -1248.4
BRKR: 9.27
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: 2.94, Med: 5.66, Max: 9.27
Current: 9.27
2.94
9.27
ROC (Joel Greenblatt) % 38.09
ROC (Joel Greenblatt) ranked higher than
77.99% of 259 companies
in the Diagnostics & Research industry.
Industry Max: 17601.65, Med: -9.57, Min: -3842027.78
BRKR: 38.09
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: 19.4, Med: 33.65, Max: 40.15
Current: 38.09
19.4
40.15
3-Year Total Revenue Growth Rate 5.30
3-Year Revenue Growth Rate ranked lower than
61.54% of 182 companies
in the Diagnostics & Research industry.
Industry Max: 371, Med: 4.8, Min: -100
BRKR: 7.9
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: 9.7, Max: 43.4
Current: 7.9
0
43.4
3-Year Total EBITDA Growth Rate 18.40
3-Year EBITDA Growth Rate ranked higher than
66.29% of 178 companies
in the Diagnostics & Research industry.
Industry Max: 141.7, Med: 10.1, Min: -340.1
BRKR: 21.3
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: 8.2, Max: 310.4
Current: 21.3
0
310.4
3-Year EPS w/o NRI Growth Rate 23.90
3-Year EPS w/o NRI Growth Rate ranked higher than
56.44% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 138.7, Med: 10.1, Min: -301
BRKR: 23.9
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -1.6, Max: 59.6
Current: 23.9
0
59.6

» BRKR's 30-Y Financials

Financials (Next Earnings Date: 2019-08-02)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:BRKR

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Diagnostics & Research    NAICS : 334516    SIC : 3826
Compare NAS:GH NYSE:CRL MIL:DIA NAS:PRAH NAS:ICLR XPAR:ERF NYSE:QGEN NYSE:BIO NAS:SYNH SHSE:603658 NYSE:PKI XPAR:BIM SZSE:300676 NAS:NEOG NAS:DXCM BSP:DASA3 NAS:QDEL SHSE:603882 NAS:NEO NAS:MEDP
Traded in other countries BKD.Germany
Address 40 Manning Road, Billerica, MA, USA, 01821
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. The vast majority of revenue comes from the scientific instruments segment, which develops tools based on magnetic resonance, mass spectrometry, and X-ray technologies. The remainder of the firm's business comes from the energy and superconductor technology segment, which manufactures superconducting materials primarily used in magnetic resonance imaging, nuclear magnetic resonance, and fusion energy research. The largest proportion of Bruker's revenue comes from Europe, though the firm also has a significant presence in the United States and Asia.

Ratios

Current vs industry vs history
PE Ratio (TTM) 38.62
PE Ratio ranked lower than
79.65% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35, Min: 0.33
BRKR: 38.62
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 7.21, Med: 32.47, Max: 73.45
Current: 38.62
7.21
73.45
Forward PE Ratio 28.01
Forward P/E ranked higher than
57.50% of 40 companies
in the Diagnostics & Research industry.
Industry Max: 78.74, Med: 9999, Min: 11.64
BRKR: 28.01
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 38.62
PE without NRI ranked lower than
79.65% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35.56, Min: 0.34
BRKR: 38.62
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 7.21, Med: 32.47, Max: 73.45
Current: 38.62
7.21
73.45
Price-to-Owner-Earnings 51.62
Price-to-Owner-Earnings ranked lower than
64.47% of 76 companies
in the Diagnostics & Research industry.
Industry Max: 1523.53, Med: 36.75, Min: 4.91
BRKR: 51.62
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 10.85, Med: 40.25, Max: 6933.33
Current: 51.62
10.85
6933.33
PB Ratio 7.92
PB Ratio ranked lower than
68.16% of 245 companies
in the Diagnostics & Research industry.
Industry Max: 270, Med: 4.02, Min: 0.15
BRKR: 7.92
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.93, Med: 4.8, Max: 8.92
Current: 7.92
1.93
8.92
PS Ratio 3.70
PS Ratio ranked higher than
62.61% of 230 companies
in the Diagnostics & Research industry.
Industry Max: 6350, Med: 3.81, Min: 0.07
BRKR: 3.7
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.5, Med: 1.93, Max: 3.81
Current: 3.7
0.5
3.81
Price-to-Free-Cash-Flow 45.13
Price-to-Free-Cash-Flow ranked lower than
68.75% of 80 companies
in the Diagnostics & Research industry.
Industry Max: 1356.19, Med: 29.22, Min: 0.35
BRKR: 45.13
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 10.25, Med: 30.38, Max: 147.38
Current: 45.13
10.25
147.38
Price-to-Operating-Cash-Flow 34.08
Price-to-Operating-Cash-Flow ranked lower than
67.01% of 97 companies
in the Diagnostics & Research industry.
Industry Max: 1739.7, Med: 19.94, Min: 0.35
BRKR: 34.08
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 5.71, Med: 21.54, Max: 50.96
Current: 34.08
5.71
50.96
EV-to-EBIT 27.72
EV-to-EBIT ranked higher than
58.47% of 118 companies
in the Diagnostics & Research industry.
Industry Max: 341.21, Med: 25.06, Min: 5.74
BRKR: 27.72
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: 4.7, Med: 21.05, Max: 33.6
Current: 27.72
4.7
33.6
EV-to-EBITDA 21.91
EV-to-EBITDA ranked higher than
60.61% of 132 companies
in the Diagnostics & Research industry.
Industry Max: 486.47, Med: 20.75, Min: 3.94
BRKR: 21.91
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: 4.3, Med: 16, Max: 22.44
Current: 21.91
4.3
22.44
EV-to-Revenue 3.72
EV-to-Revenue ranked higher than
67.36% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 19679, Med: 4.24, Min: 0.09
BRKR: 3.72
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 0.6, Med: 1.9, Max: 3.6
Current: 3.72
0.6
3.6
PEG Ratio 2.51
PEG Ratio ranked lower than
77.08% of 48 companies
in the Diagnostics & Research industry.
Industry Max: 128.13, Med: 3.26, Min: 0.32
BRKR: 2.51
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 0.09, Med: 2.83, Max: 270.82
Current: 2.51
0.09
270.82
Shiller PE Ratio 67.37
Shiller PE Ratio ranked higher than
53.85% of 39 companies
in the Diagnostics & Research industry.
Industry Max: 459.08, Med: 52.49, Min: 10.19
BRKR: 67.37
Ranked among companies with meaningful Shiller PE Ratio only.
Shiller PE Ratio range over the past 10 years
Min: 35.08, Med: 49.83, Max: 109.21
Current: 67.37
35.08
109.21
Current Ratio 2.12
Current Ratio ranked higher than
50.80% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.58, Min: 0.02
BRKR: 2.12
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.26, Med: 2.22, Max: 4.99
Current: 2.12
1.26
4.99
Quick Ratio 1.27
Quick Ratio ranked lower than
61.20% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.14, Min: 0.02
BRKR: 1.27
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.43, Med: 1.3, Max: 3.95
Current: 1.27
0.43
3.95
Days Inventory 187.73
Days Inventory ranked lower than
85.29% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 917.88, Med: 79.76, Min: 0.37
BRKR: 187.73
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 178.02, Med: 199.13, Max: 259.2
Current: 187.73
178.02
259.2
Days Sales Outstanding 68.32
Days Sales Outstanding ranked higher than
51.47% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 521.64, Med: 67.51, Min: 1
BRKR: 68.32
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 52.76, Med: 60.67, Max: 68.78
Current: 68.32
52.76
68.78
Days Payable 45.72
Days Payable ranked lower than
77.54% of 187 companies
in the Diagnostics & Research industry.
Industry Max: 981.81, Med: 63.34, Min: 1
BRKR: 45.72
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 26.4, Med: 29.9, Max: 45.72
Current: 45.72
26.4
45.72

Dividend & Buy Back

Current vs industry vs history
Dividend Yield % 0.35
Trailing Dividend Yield ranked lower than
69.42% of 121 companies
in the Diagnostics & Research industry.
Industry Max: 10.16, Med: 0.81, Min: 0.07
BRKR: 0.35
Ranked among companies with meaningful Trailing Dividend Yield only.
Trailing Dividend Yield range over the past 10 years
Min: 0.14, Med: 0.52, Max: 0.76
Current: 0.35
0.14
0.76
Dividend Payout Ratio 0.14
Dividend Payout Ratio ranked higher than
77.14% of 70 companies
in the Diagnostics & Research industry.
Industry Max: 6.35, Med: 0.32, Min: 0.03
BRKR: 0.14
Ranked among companies with meaningful Dividend Payout Ratio only.
Dividend Payout Ratio range over the past 10 years
Min: 0.14, Med: 0.17, Max: 0.33
Current: 0.14
0.14
0.33
Forward Dividend Yield % 0.35
Forward Dividend Yield ranked lower than
71.68% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 10.53, Med: 1.1, Min: 0.07
BRKR: 0.35
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield-on-Cost (5-Year) % 0.35
Yield-on-Cost (5y) ranked lower than
80.28% of 142 companies
in the Diagnostics & Research industry.
Industry Max: 12, Med: 1.41, Min: 0.08
BRKR: 0.35
Ranked among companies with meaningful Yield-on-Cost (5y) only.
Yield-on-Cost (5y) range over the past 10 years
Min: 0.14, Med: 0.52, Max: 0.76
Current: 0.35
0.14
0.76
3-Year Share Buyback Rate 1.80
3-Year Share Buyback Rate ranked higher than
98.33% of 180 companies
in the Diagnostics & Research industry.
Industry Max: 3.4, Med: -7.9, Min: -1732.6
BRKR: 1.8
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -22.1, Med: -3.1, Max: 0
Current: 1.8
-22.1
0

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 19.98
Price-to-Tangible-Book ranked lower than
71.98% of 207 companies
in the Diagnostics & Research industry.
Industry Max: 272.36, Med: 6.46, Min: 0.21
BRKR: 19.98
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.34, Med: 5.52, Max: 20.49
Current: 19.98
1.34
20.49
Price-to-Projected-FCF 3.24
Price-to-Intrinsic-Value-Projected-FCF ranked lower than
60.00% of 75 companies
in the Diagnostics & Research industry.
Industry Max: 449, Med: 2.41, Min: 0.47
BRKR: 3.24
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.91, Med: 2.3, Max: 10.62
Current: 3.24
0.91
10.62
Price-to-Median-PS-Value 1.93
Price-to-Median-PS-Value ranked lower than
73.06% of 193 companies
in the Diagnostics & Research industry.
Industry Max: 7.22, Med: 1.01, Min: 0.01
BRKR: 1.93
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.31, Med: 0.94, Max: 21.65
Current: 1.93
0.31
21.65
Price-to-Peter-Lynch-Fair-Value 2.35
Price-to-Peter-Lynch-Fair-Value ranked lower than
96.67% of 30 companies
in the Diagnostics & Research industry.
Industry Max: 15.31, Med: 2.01, Min: 0.83
BRKR: 2.35
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0.4, Med: 1.8, Max: 13.14
Current: 2.35
0.4
13.14
Price-to-Graham-Number 5.86
Price-to-Graham-Number ranked lower than
78.95% of 76 companies
in the Diagnostics & Research industry.
Industry Max: 49.42, Med: 3.98, Min: 0.39
BRKR: 5.86
Ranked among companies with meaningful Price-to-Graham-Number only.
Price-to-Graham-Number range over the past 10 years
Min: 1.07, Med: 3.17, Max: 16.03
Current: 5.86
1.07
16.03
Earnings Yield (Joel Greenblatt) % 3.63
Earnings Yield (Greenblatt) ranked higher than
81.89% of 265 companies
in the Diagnostics & Research industry.
Industry Max: 17.42, Med: -0.98, Min: -1428.57
BRKR: 3.63
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: 3, Med: 4.75, Max: 21.4
Current: 3.63
3
21.4
Forward Rate of Return (Yacktman) % 18.35
Forward Rate of Return ranked higher than
52.86% of 70 companies
in the Diagnostics & Research industry.
Industry Max: 7802.99, Med: 8.45, Min: -35.9
BRKR: 18.35
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: -1.9, Med: 10.6, Max: 25.7
Current: 18.35
-1.9
25.7

More Statistics

Revenue (TTM) (Mil) $ 1,925.3
EPS (TTM) $ 1.18
Beta 1.44
Volatility % 29.79
52-Week Range $ 26.1 - 46.74
Shares Outstanding (Mil) 156.82

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y